Anavex Life Sciences Corp (NASDAQ:AVXL) — Market Cap & Net Worth
Market Cap & Net Worth: Anavex Life Sciences Corp (AVXL)
Anavex Life Sciences Corp (NASDAQ:AVXL) has a market capitalization of $231.68 Million ($231.68 Million) as of August 6, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15987 globally and #3752 in its home market, demonstrating a 26.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Anavex Life Sciences Corp's stock price $3.15 by its total outstanding shares 92671758 (92.67 Million). Review AVXL FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
Anavex Life Sciences Corp Market Cap History: 2015 to 2026
Anavex Life Sciences Corp's market capitalization history from 2015 to 2026. Data shows change from $516.18 Million to $291.92 Million (-9.39% CAGR).
Index Memberships
Anavex Life Sciences Corp is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.48 Trillion | 0.01% | #435 of 976 |
|
NASDAQ Composite
IXIC
|
$41.12 Trillion | 0.00% | #1565 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.74 Trillion | 0.01% | #220 of 263 |
Weight: Anavex Life Sciences Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Anavex Life Sciences Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Anavex Life Sciences Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
-350.39x
Anavex Life Sciences Corp's market cap is -350.39 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $240.02 Million | $-685.00K | -$26.29 Million | -350.39x | N/A |
Competitor Companies of AVXL by Market Capitalization
Companies near Anavex Life Sciences Corp in the global market cap rankings as of August 6, 2026.
Key companies related to Anavex Life Sciences Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #427 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #544 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #569 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $478.71 |
| #427 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $760.66 |
| #544 | Argen-X | BR:ARGX | $49.55 Billion | €728.00 |
| #569 | UCB SA | BR:UCB | $47.34 Billion | €223.30 |
Anavex Life Sciences Corp Historical Marketcap From 2015 to 2026
Between 2015 and today, Anavex Life Sciences Corp's market cap moved from $516.18 Million to $ 291.92 Million, with a yearly change of -9.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $291.92 Million | -11.52% |
| 2025 | $329.91 Million | -66.85% |
| 2024 | $995.29 Million | +15.36% |
| 2023 | $862.77 Million | +0.54% |
| 2022 | $858.14 Million | -46.60% |
| 2021 | $1.61 Billion | +221.11% |
| 2020 | $500.43 Million | +108.49% |
| 2019 | $240.02 Million | +66.03% |
| 2018 | $144.57 Million | -51.55% |
| 2017 | $298.40 Million | -18.69% |
| 2016 | $366.98 Million | -28.90% |
| 2015 | $516.18 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 5th, 2026 the market cap of Anavex Life Sciences Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $231.68 Million USD |
| MoneyControl | $231.68 Million USD |
| MarketWatch | $231.68 Million USD |
| marketcap.company | $231.68 Million USD |
| Reuters | $231.68 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Anavex Life Sciences Corp
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), h… Read more